These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34174217)

  • 21. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2.
    Natsuaki M; Furukawa Y; Morimoto T; Nakagawa Y; Ono K; Kaburagi S; Inada T; Mitsuoka H; Taniguchi R; Nakano A; Kita T; Sakata R; Kimura T;
    Circ J; 2012; 76(6):1369-79. PubMed ID: 22447012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
    Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
    J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).
    Liu PY; Lin LY; Lin HJ; Hsia CH; Hung YR; Yeh HI; Wu TC; Chen JY; Chien KL; Chen JW
    PLoS One; 2013; 8(10):e76298. PubMed ID: 24098467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease.
    Moroi M; Nagayama D; Hara F; Saiki A; Shimizu K; Takahashi M; Sato N; Shiba T; Sugimoto H; Fujioka T; Chiba T; Nishizawa K; Usui S; Iwasaki Y; Tatsuno I; Sugi K; Yamasaki J; Yamamura S; Shirai K
    Int J Cardiol; 2020 Apr; 305():139-146. PubMed ID: 31987664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysis.
    Ford I; Bezlyak V; Stott DJ; Sattar N; Packard CJ; Perry I; Buckley BM; Jukema JW; de Craen AJ; Westendorp RG; Shepherd J
    PLoS Med; 2009 Jan; 6(1):e16. PubMed ID: 19166266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome.
    Nakazawa M; Arashi H; Yamaguchi J; Ogawa H; Hagiwara N
    Atherosclerosis; 2020 Jun; 303():21-28. PubMed ID: 32474302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
    Damask A; Steg PG; Schwartz GG; Szarek M; Hagström E; Badimon L; Chapman MJ; Boileau C; Tsimikas S; Ginsberg HN; Banerjee P; Manvelian G; Pordy R; Hess S; Overton JD; Lotta LA; Yancopoulos GD; Abecasis GR; Baras A; Paulding C;
    Circulation; 2020 Feb; 141(8):624-636. PubMed ID: 31707832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Relationship between estimated glomerular filtration rate level and clinical characteristics and outcome in patients with angiographic coronary artery disease and normal serum creatinine].
    Li Q; Gao YC; He JQ; Jiang TY; Ren XJ; Chen F
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Jul; 41(7):563-7. PubMed ID: 24284182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events.
    Sakuma M; Iimuro S; Shinozaki T; Kimura T; Nakagawa Y; Ozaki Y; Iwata H; Miyauchi K; Daida H; Suwa S; Sakuma I; Nishihata Y; Saito Y; Ogawa H; Matsuzaki M; Ohashi Y; Taguchi I; Toyoda S; Inoue T; Nagai R
    BMC Med; 2022 Nov; 20(1):441. PubMed ID: 36372869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of preventive effect on cardiovascular events with different statins. -The CIRCLE study-.
    Maruyama T; Takada M; Nishibori Y; Fujita K; Miki K; Masuda S; Horimatsu T; Hasuike T
    Circ J; 2011; 75(8):1951-9. PubMed ID: 21673458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombotic Risk Stratification and Intensive Statin Therapy for Secondary Prevention of Coronary Artery Disease　- Insights From the REAL-CAD Study.
    Natsuaki M; Morimoto T; Iimuro S; Fujita R; Iwata H; Miyauchi K; Inoue T; Nakagawa Y; Nishihata Y; Daida H; Ozaki Y; Suwa S; Sakuma I; Furukawa Y; Shiomi H; Watanabe H; Yamaji K; Saito N; Matsuzaki M; Nagai R; Kimura T;
    Circ J; 2022 Aug; 86(9):1416-1427. PubMed ID: 35934778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contribution of apolipoprotein A-I to the reduction in high-sensitivity C-reactive protein levels by different statins: comparative study of pitavastatin and atorvastatin.
    Tani S; Takahashi A; Nagao K; Hirayama A
    Heart Vessels; 2015 Nov; 30(6):762-70. PubMed ID: 25062713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statins combined with exercise are associated with the increased renal function mediated by high-molecular-weight adiponectin in coronary artery disease patients.
    Toyama K; Sugiyama S; Oka H; Iwasaki Y; Sumida H; Tanaka T; Tayama S; Jinnouchi H; Ogawa H
    J Cardiol; 2014 Aug; 64(2):91-7. PubMed ID: 24457019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study.
    Lee HY; Cho HJ; Kim HY; Jeon HK; Shin JH; Kang SM; Baek SH
    Korean J Intern Med; 2014 Nov; 29(6):754-63. PubMed ID: 25378974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of coronary lesions complexity in patients with stable coronary artery disease.
    Aksakal E; Tanboga IH; Kurt M; Kaya A; Topcu S; Kalkan K; Sevimli S
    Angiology; 2013 May; 64(4):304-9. PubMed ID: 23172583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.